Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma

Journal of Pathology

Volumn 183, Issue 3, 1997, Pages 318-324

  Ito, Kiyoshi ^a   Sasano, Hironobu ^a   Matsunaga, Gen ^a   Sato, Shinji ^a   Yajima, Akira ^a   Nasim, Suhail ^b   Garret, Carleton T ^b  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinoma; Endometrium; Immunohistochemistry; P21; P53; PCR SSCP

Indexed keywords

CYCLIN DEPENDENT KINASE; PROTEIN P21; PROTEIN P53;

ARTICLE; CANCER SURVIVAL; CELL CYCLE; CELL DIFFERENTIATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM;

CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, P53; HUMANS; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030665835     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199711)183:3<318::AID-PATH925>3.0.CO;2-0     Document Type: Article

References (26)

1. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523-526.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
3. Ito K, Watanabe K, Nasim S, et al. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res 1994; 54: 4667-4670.
4. Kohler MF, Berchuck A, Davidoff AM, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992; 52: 1622-1627.
5. Bur ME, Perlman C, Edelmann L, Fey E, Rose PG. p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 1992; 98: 81-87.
6. Sasano H, Watanabe K, Ito K, Sato S, Yajima A. New concepts in the diagnosis and prognosis of endometrial carcinoma Pathol Annu 1994; 29: 31-49.
7. Jiko K, Sasano H, Ito K, Ozawa N, Sato S, Yajima A. Immunohistochemistry and in situ hybridization analysis of p53 in human endometrial carcinoma of the uterus. Anticancer Res 1993; 13: 305-310.
8. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-6311.
9. Kastan MB, Zhan Q, EL-Deiry WS, et al. A mammalian cell cycle check point pathway utilizing p53 and GADD45 is defective in ataxiatelangiectasia. Cell 1992; 71: 587-597.
10. EL-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
11. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 in human cancer cells. Cancer Res 1995; 55: 5187-5190.
12. Sheikh MS, Li XS, Chen JC, Shao ZM, Ordonez JV, Fontana JA. Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: role of p53-dependent and -independent signal transduction pathways. Oncogene 1994; 9: 3407-3415.
13. Zing Y, EL-Deiry WS. Regulation of p21 WAF1/CIP1 expression by p53-independent pathways. Oncogene 1996; 12: 1557-1564.
14. EL-Deiry WS, Tokino T, Waldman T, et al. Topological control of p21 WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995; 55: 2910-2919.
15. Johnson M, Dimitrov D, Vojta PJ, et al. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 mRNA in human cells. Mol Carcinogenesis 1994; 11: 59-64.
16. Halevy O, Novitch BG, Spicer DB, et al. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995; 267: 1018-1021.
17. FIGO News, Int J Gynecol Obstet 1989; 28: 139.
18. Sasano H, Imatani A, Shizawa S, Suzuki T, Nagura H. Cell proliferation and apoptosis in normal and pathologic human adrenal. Mod Pathol 1995; 8: 11-17.
19. Orita M, Suzuki Y, Hayashi K. Rapid and sensitive detection of point mutation and DNA polymorphisms using the polymerase chain reaction. Genomics 1989; 5: 874-879.
20. WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status. MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer 1996; 74: 208-215.
21. Marchetti A, Doglioni C, Barbareschi M, et al. p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 1996; 12: 1319-1324.
22. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53 independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995; 147: 884-888.
23. Marchetti A, Buttitta F, Pellegrini S, Lori A, Bertacca G, Bevil-Lacqua G. Absence of somatic mutations in the coding region of the WAF1/CIP1 gene in human breast, lung and ovarian carcinomas: a polymorphism at codon 31. Int J Oncol 1995; 6: 187-189.
24. Steinman RA, Huffman B, Iro A, Guillouf C, Liebermann DA, El-Houseini MEE. Induction of p21 (WAF1/CIP1) during differentiation. Oncogene 1994; 9: 3389-3396.
25. Jiang H, Lin J, Su ZZ, Collart FR, Huberman E, Fisher PB. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 1994; 9: 3397-3406.
26. Parker SB, Eichele G, Zhang P, et al. p53-independent expression of p21/CIP1 in muscle and other terminally differentiating cells. Science 1995; 267: 1024-1027.